Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from The United Laboratories International Holdings ( (HK:3933) ).
The United Laboratories International Holdings has issued a clarification to its previously published annual results announcement for the year ended 31 December 2025, correcting an error in the description of its dividend arrangements. The company stated that references to a “special dividend” in the closure of register of members section should be removed, confirming that only a final dividend is applicable.
The clarification specifies the record date and share transfer cut-off for shareholders to qualify for the final dividend, with the register of members to be closed on 9 and 10 July 2026 and transfers to be lodged by 4:30 p.m. on 8 July 2026. The board emphasized that aside from this wording correction, all other information in the original results announcement remains unchanged, indicating no alteration to the company’s previously disclosed financial outcomes or dividend policy.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a Hong Kong-listed pharmaceutical group incorporated in the Cayman Islands. The company focuses on manufacturing and distributing pharmaceutical products, with its shares traded on the Main Board of the Stock Exchange of Hong Kong under stock code 3933.
Average Trading Volume: 11,356,645
Technical Sentiment Signal: Hold
Current Market Cap: HK$20.03B
Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.